Trial
NCT03382912
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
ARMO BioSciences
Condition
Non Small Cell Lung Cancer
Intervention
Pegilodecakin
Why stopped
The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-11